|
Background
Extensive surveys in Europe and Asia have shown that
postprandial hyperglycaemia is associated with an increased
cardiovascular risk and that hyperglycaemia is common in
patients with confirmed cardiovascular disease (CVD).
Postprandial hyperglycaemia
- appears to be an independent risk factor for CVD
- may provide the ‚missing link‘ that explains part of the wellknown
increased risk for patients with diabetes.
Glucobay® (Acarbose) has a unique mode of action and
provides long-term glycaemic control with beneficial effects on
hypertension, lipid profile and endothelial function – all essential
for overall CV risk reduction.
Glucobay®
- has shown to significantly reduce the rate of CVD events
in patients with prediabetes and diabetes (STOP-NIDDM;
MeRIA)
- is recommended by major guidelines as treatment for postprandial
hyperglycaemia to limit the related risk of CVD
- is the most appropriate medicine to
further test the hypothesis of bridging
the gap between postprandial
hyperglycaemia and CVD and
of providing a strategy for
prevention.
|
